Cargando…
967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis
BACKGROUND: Influenza-associated aspergillosis (IAA) is an emerging fungal infection with high mortality and morbidity and the pathogenesis of this disease is not well understood. Interestingly, the number of IAA case reports has increased since the widespread use of neuraminidase inhibitors, such a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252941/ http://dx.doi.org/10.1093/ofid/ofy209.083 |
_version_ | 1783373381371953152 |
---|---|
author | Van De Veerdonk, Frank Dewi, Intan Cunha, Christina vanderBeeke, Lore Jaeger, Martin Gresnigt, Mark Resendiz, Agustin Lagrou, Katrien Velde, Greetje Van De Wauters, Joost Carvalho, Agostinho |
author_facet | Van De Veerdonk, Frank Dewi, Intan Cunha, Christina vanderBeeke, Lore Jaeger, Martin Gresnigt, Mark Resendiz, Agustin Lagrou, Katrien Velde, Greetje Van De Wauters, Joost Carvalho, Agostinho |
author_sort | Van De Veerdonk, Frank |
collection | PubMed |
description | BACKGROUND: Influenza-associated aspergillosis (IAA) is an emerging fungal infection with high mortality and morbidity and the pathogenesis of this disease is not well understood. Interestingly, the number of IAA case reports has increased since the widespread use of neuraminidase inhibitors, such as oseltamivir in 2009. We set out to determine whether oseltamivir could contribute to the pathogenesis of IAA by modulating host responses. METHODS: First, peripheral blood mononuclear cells (PBMCs) and neutrophils from healthy donors were stimulated with neuraminidase (NA)-treated A. fumigatus or were pre-exposed to NA prior to stimulation with Aspergillus conidia. In addition, PBMCs and neutrophils were pretreated with oseltamivir carboxylate prior to stimulation. Cytokines were measured from supernatants after 24 hours of incubation at 37°C. C57BL/6 and BALB/c mice were treated with oseltamivir prior to intranasal challenge with A. fumigatus. Immunosuppression was induced by corticosteroid or cyclophosphamide. RESULTS: We demonstrate that Aspergillus treated with NA induced an enhanced immune response. Moreover, PBMCs and neutrophils treated with NA produced increased cytokine responses. Blocking NA in vitro with oseltamivir reduced Aspergillus-induced cytokine responses. Next we investigated the effects of blocking neuraminidase activity with oseltamivir in vivo. Immunocompetent mice and mice treated with corticosteroids showed increased mortality, lung fungal burden, and decreased cytokine production when treated with oseltamivir. These effects were not observed in cyclophosphamide-treated mice, suggesting that the effects of NA activity in anti-Aspergillus host defense acts mainly via myeloid cells. CONCLUSION: Our results provide evidence that host neuraminidase activity is important for protective anti-Aspergillus immune responses. Treatment with oseltamivir, thus blocking host NA activity, in a setting of corticosteroid use might therefore increase susceptibility to Aspergillus infection. These results warrant further study on the role of neuraminidase and the effects of oseltamivir on susceptibility to invasive pulmonary aspergillosis during active influenza infection. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6252941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62529412018-11-28 967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis Van De Veerdonk, Frank Dewi, Intan Cunha, Christina vanderBeeke, Lore Jaeger, Martin Gresnigt, Mark Resendiz, Agustin Lagrou, Katrien Velde, Greetje Van De Wauters, Joost Carvalho, Agostinho Open Forum Infect Dis Abstracts BACKGROUND: Influenza-associated aspergillosis (IAA) is an emerging fungal infection with high mortality and morbidity and the pathogenesis of this disease is not well understood. Interestingly, the number of IAA case reports has increased since the widespread use of neuraminidase inhibitors, such as oseltamivir in 2009. We set out to determine whether oseltamivir could contribute to the pathogenesis of IAA by modulating host responses. METHODS: First, peripheral blood mononuclear cells (PBMCs) and neutrophils from healthy donors were stimulated with neuraminidase (NA)-treated A. fumigatus or were pre-exposed to NA prior to stimulation with Aspergillus conidia. In addition, PBMCs and neutrophils were pretreated with oseltamivir carboxylate prior to stimulation. Cytokines were measured from supernatants after 24 hours of incubation at 37°C. C57BL/6 and BALB/c mice were treated with oseltamivir prior to intranasal challenge with A. fumigatus. Immunosuppression was induced by corticosteroid or cyclophosphamide. RESULTS: We demonstrate that Aspergillus treated with NA induced an enhanced immune response. Moreover, PBMCs and neutrophils treated with NA produced increased cytokine responses. Blocking NA in vitro with oseltamivir reduced Aspergillus-induced cytokine responses. Next we investigated the effects of blocking neuraminidase activity with oseltamivir in vivo. Immunocompetent mice and mice treated with corticosteroids showed increased mortality, lung fungal burden, and decreased cytokine production when treated with oseltamivir. These effects were not observed in cyclophosphamide-treated mice, suggesting that the effects of NA activity in anti-Aspergillus host defense acts mainly via myeloid cells. CONCLUSION: Our results provide evidence that host neuraminidase activity is important for protective anti-Aspergillus immune responses. Treatment with oseltamivir, thus blocking host NA activity, in a setting of corticosteroid use might therefore increase susceptibility to Aspergillus infection. These results warrant further study on the role of neuraminidase and the effects of oseltamivir on susceptibility to invasive pulmonary aspergillosis during active influenza infection. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6252941/ http://dx.doi.org/10.1093/ofid/ofy209.083 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Van De Veerdonk, Frank Dewi, Intan Cunha, Christina vanderBeeke, Lore Jaeger, Martin Gresnigt, Mark Resendiz, Agustin Lagrou, Katrien Velde, Greetje Van De Wauters, Joost Carvalho, Agostinho 967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis |
title | 967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis |
title_full | 967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis |
title_fullStr | 967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis |
title_full_unstemmed | 967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis |
title_short | 967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis |
title_sort | 967. inhibition of host neuraminidase increases susceptibility to invasive pulmonary aspergillosis |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252941/ http://dx.doi.org/10.1093/ofid/ofy209.083 |
work_keys_str_mv | AT vandeveerdonkfrank 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT dewiintan 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT cunhachristina 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT vanderbeekelore 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT jaegermartin 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT gresnigtmark 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT resendizagustin 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT lagroukatrien 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT veldegreetjevande 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT wautersjoost 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis AT carvalhoagostinho 967inhibitionofhostneuraminidaseincreasessusceptibilitytoinvasivepulmonaryaspergillosis |